Edition:
United States

Profile: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

13.19EUR
29 Apr 2016
Change (% chg)

€-0.12 (-0.86%)
Prev Close
€13.31
Open
€13.20
Day's High
€13.50
Day's Low
€13.14
Volume
42,839
Avg. Vol
174,921
52-wk High
€16.20
52-wk Low
€9.82

Search Stocks
Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis.

Company Address

Ablynx NV

Technologiepark 21, Zwijnaarde
GENT     9052
P: +329.2620000
F: +329.2620001

Company Web Links

Search Stocks